The perils of inhibiting deficient factors

J Thromb Haemost. 2018 Jun 8. doi: 10.1111/jth.14195. Online ahead of print.

Abstract

Essentials Anticoagulation in patients with factor X deficiency is an evidence-poor area. A patient with factor X deficiency was anticoagulated with warfarin followed by rivaroxaban. Warfarin may be a safer anticoagulant option than rivaroxaban in hereditary factor X deficiency. A baseline coagulation screen should be performed prior to commencement of anticoagulation.

Summary: We report a case of a previously undiagnosed factor X deficiency in an 83-year-old man who had no previous bleeding history despite multiple hemostatic challenges. He was anticoagulated with warfarin for atrial fibrillation without bleeding complications; however, major hemorrhage occurred soon after a switch to rivaroxaban.

Keywords: coagulation; factor X; oral anticaogulants; pharmacotherapeutics; rivaroxaban.